Evaxion Biotech (EVAX) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Evaxion Biotech has received a delisting determination from Nasdaq due to insufficient stockholder equity but has appealed the decision and requested a hearing to seek an additional 180-day extension. The company remains committed to maintaining its Nasdaq listing by increasing equity through business development and capital market activities. Despite challenges in the current market environment, Evaxion is in ongoing discussions with Nasdaq to regain compliance.
For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.